Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

被引:132
|
作者
Pearce, Lindsay A. [1 ]
Min, Jeong Eun [1 ]
Piske, Micah [1 ]
Zhou, Haoxuan [1 ]
Homayra, Fahmida [1 ]
Slaunwhite, Amanda [2 ]
Irvine, Mike [2 ]
McGowan, Gina [3 ]
Nosyk, Bohdan [1 ,4 ]
机构
[1] British Columbia Ctr Excellence HIV AIDS, Hlth Econ Res Unit, Vancouver, BC V6Z 1Y6, Canada
[2] British Columbia Ctr Dis Control & Prevent, Vancouver, BC V5Z 4R4, Canada
[3] British Columbia Minist Mental Hlth & Addict, Victoria, BC V8W 9P1, Canada
[4] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada
来源
关键词
PHARMACOLOGICAL-TREATMENT; METHADONE; DRUG; BUPRENORPHINE; DEPENDENCE; HEROIN; THERAPY;
D O I
10.1136/bmj.m772
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug supply. Design - Population based retrospective cohort study. Setting - Individual level linkage of five health administrative datasets capturing drug dispensations, hospital admissions, physician billing records, ambulatory care reports, and deaths in British Columbia, Canada. Participants - 55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018. Main outcome measures - All cause and cause specific crude mortality rates (per 1000 person years) to determine absolute risk of mortality and all cause age and sex standardised mortality ratios to determine relative risk of mortality compared with the general population. Mortality risk was calculated according to treatment status (on OAT, off OAT), time since starting and stopping treatment (1, 2, 3-4, 5-12, >12 weeks), and medication type (methadone, buprenorphine/naloxone). Adjusted risk ratios compared the relative risk of mortality on and off OAT over time as fentanyl became more prevalent in the illicit drug supply. Results- 7030 (12.7%) of 55 347 OAT recipients died during follow-up. The all cause standardised mortality ratio was substantially lower on OAT (4.6, 95% confidence interval 4.4 to 4.8) than off OAT (9.7, 9.5 to 10.0). In a period of increasing prevalence of fentanyl, the relative risk of mortality off OAT was 2.1 (95% confidence interval 1.8 to 2.4) times higher than on OAT before the introduction of fentanyl, increasing to 3.4 (2.8 to 4.3) at the end of the study period (65% increase in relative risk). Conclusions - Retention on OAT is associated with substantial reductions in the risk of mortality for people with opioid use disorder. The protective effect of OAT on mortality increased as fentanyl and other synthetic opioids became common in the illicit drug supply, whereas the risk of mortality remained high off OAT. As fentanyl becomes more widespread globally, these findings highlight the importance of interventions that improve retention on opioid agonist treatment and prevent recipients from stopping treatment.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Opioid overdose deaths and the expansion of opioid agonist treatment: a population-based prospective cohort study
    Rogeberg, Ole
    Bergsvik, Daniel
    Clausen, Thomas
    ADDICTION, 2022, 117 (05) : 1363 - 1371
  • [2] ASSESSING THE RISK OF OPIOID OVERDOSE AFTER OPIOID TAPER: A RETROSPECTIVE COHORT STUDY
    Perez, Hector R.
    Gosen, Matthew
    Buonora, Michele
    Cunningham, Chinazo
    Starrels, Joanna L.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S30 - S30
  • [4] The risk of fatal opioid overdose associated with the concurrent use of opioid analgesics and psychotropic medicines: A retrospective population-based cohort study
    Gisev, Natasa
    Buizen, Luke
    Bharat, Chrianna
    Larney, Sarah
    Currow, David
    Blyth, Fiona M.
    Dobbins, Timothy
    Pearson, Sallie-Anne
    Degenhardt, Louisa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 589 - 590
  • [5] CONCOMITANT USE OF OPIOID AND BENZODIAZEPINES AND THE RISK OF OPIOID OVERDOSE REQUIRING HOSPITALIZATIONS: A RETROSPECTIVE COHORT STUDY
    Dave, C.
    Alrwisan, A.
    Zhu, Y.
    Winterstein, A.
    Hartzema, A.
    VALUE IN HEALTH, 2017, 20 (05) : A212 - A212
  • [6] Non-fatal overdose risk during and after opioid agonist treatment: A primary care cohort study with linked hospitalisation and mortality records br
    Domzaridou, Eleni
    Carr, Matthew J.
    Webb, Roger T.
    Millar, Tim
    Ashcroft, Darren M.
    LANCET REGIONAL HEALTH-EUROPE, 2022, 22
  • [7] Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study
    Paul, Lauren A.
    Bayoumi, Ahmed M.
    Chen, Cynthia
    Kocovska, Elena
    Smith, Brendan T.
    Raboud, Janet M.
    Gomes, Tara
    Kendall, Claire
    Rosella, Laura C.
    Bitonti-Bengert, Lisa
    Rush, Brian
    Yu, Melissa
    Spithoff, Sheryl
    Crichlow, Frank
    Wright, Amy
    Watford, Jase
    Besharah, Jes
    Munro, Charlotte
    Taha, Sheena
    Nosyk, Bohdan
    Strike, Carol
    Manson, Heather
    Kahan, Meldon
    Leece, Pamela
    ADDICTION, 2023, 118 (04) : 686 - 697
  • [8] Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study
    Macmadu, Alexandria
    Paull, Kimberly
    Youssef, Rouba
    Batthala, Sivakumar
    Wilson, Kevin H.
    Samuels, Elizabeth A.
    Yedinak, Jesse L.
    Marshall, Brandon D. L.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 226
  • [9] Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study
    Macmadu, Alexandria
    Paull, Kimberly
    Youssef, Rouba
    Batthala, Sivakumar
    Wilson, Kevin H.
    Samuels, Elizabeth A.
    Yedinak, Jesse L.
    Marshall, Brandon D. L.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 219
  • [10] Epidemiology of Emergency Department Visits for Opioid Overdose: A Population-Based Study
    Hasegawa, Kohei
    Brown, David F. M.
    Tsugawa, Yusuke
    Camargo, Carlos A., Jr.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (04) : 462 - 471